🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

11 results for “Verona” Clear

  1. FLUOROURACIL, DOCETAXEL, OPDIVO 10 mg/mL concentrate for solution for infusion., OXALIPLATIN, CALCIUM LEVOFOLINATE, CISPLATIN, DOXORUBICIN HYDROCHLORIDE

    Verona Pharma Ireland Limited

    Gastric adenocarcinoma with peritoneal metastases

    phase 3 small molecule active

    1 trial

  2. Safinamide 100 mg PLACEBO: Safinamide 100 mg PLACEBO film-coated tablets have the same composition as the relevant Investigational Medicinal Products except for the presence of Active Substance that is missing in the placebo formulations. The missing amount of active substance Safinamide methanesulfonate is replaced in the PLACEBO formulation with the same amount of Microcrystalline cellulose, one of the excipients already present in the authorised formulation, Xadago 100 mg film-coated tablets, Xadago 50 m

    Verona Pharma Ireland Limited

    PARKINSON’S DISEASE WITH MOTOR FLUCTUATIONS

    phase 3 small molecule active

    1 trial

  3. Lynparza 150 mg film-coated tablets, Lynparza 100 mg film-coated tablets

    Verona Pharma Ireland Limited

    Patients with metastatic PDAC, who have not progressed following completion of at least 16 weeks (can be more) of any multiagent first-line chemotherapy

    phase 2 small molecule active

    1 trial

  4. TAMOXENE 20 mg compresse rivestite con film

    Verona Pharma Ireland Limited

    cystic fibrosis

    phase 2 small molecule active

    1 trial

  5. Teicoplanina Sandoz 200 mg polvere e solvente per soluzione iniettabile o infusione o soluzione orale

    Verona Pharma Ireland Limited

    cystic fibrosis associated to persistent Staphylococcus aureus (including MRSA) infection

    phase 2 small molecule active

    1 trial

  6. XEOMIN, 100 unità, polvere per soluzione iniettabile

    Verona Pharma Ireland Limited

    multifocal spasticity of the upper and lower limb due to cerebral palsy

    phase 2 small molecule active

    1 trial

  7. A randomised, open-label, parallel group study to compare the pharmacokinetics and pharmacodynamics of NEODIDRO® 0.266 mg vs DIBASE® 25,000 IU oral doses in male and female patients.

    Verona Pharma Ireland Limited

    Patients with low Vitamin D plasma level

    phase 1 other active

    1 trial

  8. Mayzent 0.25 mg film-coated tablets, Mayzent 2 mg film-coated tablets

    Verona Pharma Ireland Limited

    patients with secondary progressive MS

    approved small molecule active

    1 trial

  9. Mayzent 0.25 mg film-coated tablets, Mayzent 2 mg film-coated tablets, Mayzent 1 mg film-coated tablets, BAF312, BAF312, BAF312

    Verona Pharma Ireland Limited

    Active progressive multiple sclerosis course after an initial relapse clinical course

    approved small molecule active

    1 trial

  10. Zaredrop 75 mg/ml soluzione orale, Laroxyl 40 mg/ml gocce orali soluzione, FLUOXETINA DOC Generici 20 mg/5 ml Soluzione orale, Zoloft 20 mg/ml concentrato per soluzione orale, Brintellix 20 mg/ml oral drops, solution, Daparox 33,1 mg/ml, gocce orali, soluzione., CITALOPRAM ABC 40 mg/ml gocce orali, soluzione, ESCITALOPRAM DOC 20 mg/ml gocce orali, soluzione

    Verona Pharma Ireland Limited

    Patients with currently remitted depressive disorders.

    approved small molecule active

    1 trial

  11. Zeposia 0.92 mg hard capsules

    Verona Pharma Ireland Limited

    Relapsing Multiple Sclerosis (relapsing-remitting, relapsing-progressive)

    approved small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources